Merck Announces Emerging Biotech Grant Program Winners
data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...
AOL18d
Where Will Merck Be in 5 Years?
Not everything will make it to market, but I expect many brand-new approvals and label expansions through 2029. There is one crucial headwind Merck could face in the coming years: Summit ...
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1
Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...
AFP15d
Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies
Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...
STAT15d
A drug may cause problems with chemotherapies in cancer patients with obesity. Many doctors are in the dark
A drug used by cancer patients may make chemotherapies less effective in patients with obesity — but many doctors are in the ...
AFP1d
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...
Citius Pharmaceuticals, Citius Oncology report promising cancer trial results
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...